UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscalquarterly period ended:ended September 30, 20172022

 

or

 

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ________ to ________

 

Commission File Number:333-169397

 

China Herb Group Holdings CorporationTengjun Biotechnology Corp.

(Exact name of small business issuer as specified in its charter)

 

Nevada 333-16939727-3042462

(State or other jurisdiction

of incorporation)

 (Commission File Number)

(I.R.S. Employer

Identification Number)

 

527 Siltstone Place,East Jinze Road and South Huimin Road, Food Industry Economic and Technology Development District,
Jianxiang County, Jining City, Shandong Province, China 

Cary, NC 27519

(Address of principal executive offices and zip code)

 

Phone:(86) 0537-8711599 (919) 869-0279

(Registrant’s telephone number, including area code)

 

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the last 90 days. YES NO

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of RegulationsRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES Yes     NO No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filerAccelerated filer
Non-accelerated filer (Do not check if a smaller reporting company)Smaller reporting company
 Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES NO

 

State theThe number of shares outstanding of each of the issuer’s classes ofRegistrant’s common equity,stock, $0.001 par value per share, outstanding as of the latest practicable date: 38,136,540 Shares of Common Stock, as of October 27, 2017.November 9, 2022, was 96,309,169.

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading SymbolName of each exchange on which registered
Not applicableNot applicableNot applicable

 

 

INDEXTABLE OF CONTENTS

Page No.
PART II. - FINANCIAL INFORMATION
Item 1.Financial Statements1
Item 2.Management'sManagement’s Discussion and Analysis of Financial Condition and Results of Operations716
Item 3.Quantitative and Qualitative Disclosures About Market Risk925
Item 4.Controls and Procedures1025
PART II - OTHER INFORMATION
Item 1.Legal Proceedings1126
Item 1A.Risk Factors1126
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds1126
Item 3.Defaults Uponupon Senior Securities1126
Item 4.Mine Safety Disclosures1126
Item 5.Other Information1126
Item 6.Exhibits1126
SIGNATURESignatures1227

 

i

 

PART 1 - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

 

CHINA HERB GROUP HOLDINGS CORPORATIONTENGJUN BIOTECHNOLOGY CORP. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

 

  As of 
  September 30, 2017  December 31, 2016 
  (Unaudited)    
       
ASSETS      
CURRENT ASSETS:      
Cash and cash equivalents $-  $- 
Prepaid expenses  5,833   4,367 
         
TOTAL CURRENT ASSETS  5,833   4,367 
         
TOTAL ASSETS $5,833  $4,367 
         
LIABILITIES AND STOCKHOLDERS' DEFICIT        
         
CURRENT LIABILITIES:        
Accounts payable and accrued liabilities $14,100  $11,361 
Advances for common stock purchases  2,937   - 
Related party loans  201,376   195,072 
         
TOTAL CURRENT LIABILITIES  218,413   206,433 
         
STOCKHOLDERS' DEFICIT:        
Preferred stock ($.001 par value; 5,000,000 shares authorized;        
0 shares issued and outstanding)  -   - 
Common stock ($.001 par value; 70,000,000 shares authorized;        
38,136,540 and 37,493,120 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively) 
 
 
 
 
38,137
 
 
 
 
 
 
 
37,493
 
 
Additional paid-in capital  158,764   128,411 
Accumulated deficit  (409,481)  (367,970)
         
TOTAL STOCKHOLDERS' DEFICIT  (212,580)  (202,066)
         
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $5,833  $4,367 
  September 30,  December 31, 
  2022  2021 
  (Unaudited)    
Assets      
Current Assets      
Cash and cash equivalents $3,895,968  $285,568 
Advance to suppliers  509,377   564,846 
Inventories, net  1,377,411   3,084,157 
Prepaid taxes  -   688,272 
Due from related party  1,105   - 
Loan to third parties  21,409,853   - 
Other receivable  28,704   5,688 
Total Current Assets  27,222,418   4,628,531 
         
Property and equipment, net  390,042   675,556 
Construction in progress  8,044,587   8,726,299 
         
Total Assets $35,657,047  $14,030,386 
         
Liabilities and Equity (Deficit)        
         
Current Liabilities        
Accounts payable $2,544,645  $263,891 
Advances from customers  43,581   14,123 
Due to related parties  11,419,030   15,531,258 
Accrued liabilities and other payables  13,656,318   506,844 
Total Current Liabilities  27,663,574   16,316,116 
         
Total Liabilities  27,663,574   16,316,116 
         
Equity (Deficit)        
Preferred stock, $.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding  -   - 
Common stock, $.001 par value; 200,000,000 shares authorized;  90,309,169 and 65,309,169 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively  90,309   65,309 
Additional paid-in capital  3,574,599   1,099,599 
Subscribed stock  300,000   - 
Retained earnings (accumulated deficit)  4,377,684   (3,187,804)
Accumulated other comprehensive loss  (650,627)  (168,535)
Total stockholders’ equity (deficit)  7,691,965   (2,191,431)
Noncontrolling interests  301,508   (94,299)
Total Equity (Deficit)  7,993,473   (2,285,730)
         
Total Liabilities and Equity (Deficit) $35,657,047  $14,030,386 

 

The accompanying notes to the unaudited financial statements are an integral part of these statements.consolidated financial statements

 

1


 

 

CHINA HERB GROUP HOLDINGS CORPORATIONTENGJUN BIOTECHNOLOGY CORP. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONSINCOME AND COMPREHENSIVE INCOME (LOSS)

(UNAUDITED)

 

  For the Three Months Ended September 30,  For the Nine Months Ended September 30, 
  2017  2016  2017  2016 
  (Unaudited)  (Unaudited)  (Unaudited)  (Unaudited) 
             
Revenues $-  $-  $-  $- 
                 
Operating Expenses:                
General and administrative  4,156   8,750   14,867   15,516 
Accounting fees  1,700   2,700   11,950   11,150 
Consulting fees  -   -   3,000   - 
                 
Total Operating Expenses  5,856   11,450   29,817   26,666 
                 
Loss from Operations  (5,856)  (11,450)  (29,817)  (26,666)
                 
Other Expense:                
Interest expense - related parties  (3,977)  (3,634)  (11,694)  (10,003)
                 
Total Other Expense  (3,977)  (3,634)  (11,694)  (10,003)
                 
Net Loss $(9,833) $(15,084) $(41,511) $(36,669)
                 
Net loss per common share, basic and diluted $(0.000) $(0.000) $(0.001) $(0.001)
                 
Weighted average number of common shares outstanding:                
Basic and diluted  37,856,792   36,979,533   37,615,676   36,623,229 
  For the Three Months Ended  For the Nine Months Ended 
  September 30,  September 30, 
  2022  2021  2022  2021 
             
Sales revenue, net $36,418,104  $-  $91,992,680  $- 
Cost of goods sold  2,207,304   -   6,016,317   - 
Gross profit  34,210,800   -   85,976,363   - 
Selling and marketing expenses  28,990,991   9,188   75,301,827   26,066 
General and administrative expenses  338,716   98,362   837,989   462,167 
Total operating expenses  29,329,707   107,550   76,139,816   488,233 
Income (loss) from operations  4,881,093   (107,550)  9,836,547   (488,233)
Interest income (expense)  6,273   18   13,694   (4,959)
Other income (expense), net  (7,144)  230   (7,218)  (2,290)
Income (loss) before provision for income taxes  4,880,222   (107,302)  9,843,023   (495,482)
Provision for income taxes  1,265,644   -   1,861,830   - 
Net income (loss)  3,614,578   (107,302)  7,981,193   (495,482)
Net income (loss) attributable to noncontrolling interests  189,056   -   415,705   - 
Net income (loss) attributable to Tengjun stockholders  3,425,522   (107,302)  7,565,488   (495,482)
                 
Net income (loss)  3,614,578   (107,302)  7,981,193   (495,482)
Other comprehensive income (loss):                
Foreign currency translation loss  (446,051)  (3,676)  (501,990)  (16,972)
Comprehensive income (loss)  3,168,527   (110,978)  7,479,203   (512,454)
Comprehensive income (loss) attributable to noncontrolling interests  171,983   -   395,807   - 
Comprehensive income (loss) attributable to Tengjun stockholders $2,996,544  $(110,978) $7,083,396  $(512,454)
                 
Net Income (Loss) Per Common Share:                
Net income (loss) per common share - basic and diluted $0.04  $(0.01) $0.10  $(0.03)
                 
Weighted average shares outstanding:                
Basic and diluted  88,678,734   19,285,714   73,184,627   19,285,714 

 

The accompanying notes to the unaudited financial statements are an integral part of these consolidated financial statements.

 

2

 

 

CHINA HERB GROUP HOLDINGS CORPORATIONTENGJUN BIOTECHNOLOGY CORP. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWCHANGES IN EQUITY (DEFICIT)

(UNAUDITED)

 

  For the Nine Months Ended
September 30,
 
  2017  2016 
  (Unaudited)  (Unaudited) 
       
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net loss $(41,511) $(36,669)
Adjustments to reconcile net loss to net cash used in operating activities:        
Imputed interest on related parties loans  11,694   10,003 
Changes in operating assets and liabilities:        
Increase in prepaid expenses  (1,466)  (7,792)
Increase (decrease) in accounts payable and accrued liabilities  2,739   (3,180)
         
NET CASH USED IN OPERATING ACTIVITIES  (28,544)  (37,638)
         
CASH FLOWS FROM FINANCING ACTIVITIES:        
Proceeds received as advance for future common stock subscriptions  2,937   - 
Bank overdrafts  -   36 
Proceeds from sale of common stock  19,303   1,050 
Proceeds received from loans from officer  28,544   34,757 
Repayments made for loans from officer  (22,240)  - 
         
NET CASH PROVIDED BY FINANCING ACTIVITIES  28,544   35,843 
         
NET DECREASE IN CASH  -   (1,795)
         
Cash, beginning of period  -   1,795 
         
Cash, end of period $-  $- 
         
SUPPLEMENTAL DISCLOSURES:        
Interest paid $-  $- 
Income taxes paid $-  $- 
              

Retained

  Accumulated       
        Additional     Earnings  Other     Total 
  Common Stock  Paid-in  Subscribed  (Accumulated  Comprehensive  Noncontrolling  Equity 
  Shares  Amount  Capital  Stock  Deficit)  Loss  Interests  (Deficit) 
Balance at December 31, 2021  65,309,169  $65,309  $1,099,599  $-  $(3,187,804) $(168,535) $(94,299) $(2,285,730)
Net income  -   -   -   -   218,823   -   13,984   232,807 
Foreign currency translation  -   -   -   -   -   (8,961)  (477)  (9,438)
Balance at March 31, 2022  65,309,169   65,309   1,099,599   -   (2,968,981)  (177,496)  (80,792)  (2,062,361)
Net income (restated)  -   -   -   -   3,921,143   -   212,665   4,133,808 
Foreign currency translation (restated)  -   -   -   -   -   (44,153)  (2,348)  (46,501)
Balance at June 30, 2022 (restated)  65,309,169   65,309   1,099,599   -   952,162   (221,649)  129,525   2,024,946 
Issuance of common stock  25,000,000   25,000   2,475,000   -   -   -   -   2,500,000 
Common stock subscriptions received in advance  -   -  ��-   300,000   -   -   -   300,000 
Net income  -   -   -   -   3,425,522   -   189,056   3,614,578 
Foreign currency translation  -   -   -   -   -   (428,978)  (17,073)  (446,051)
Balance at September 30, 2022  90,309,169  $90,309  $3,574,599  $300,000  $4,377,684  $(650,627) $301,508  $7,993,473 
                                 
                 Accumulated       
        Additional        Other       
  Common Stock  Paid-in  Subscribed  Accumulated  Comprehensive  Noncontrolling  Total 
  Shares  Amount  Capital  Stock  Deficit  Loss  Interests  Deficit 
Balance at December 31, 2020  19,285,714  $19,286  $1,549,018  $                    -  $(2,605,211) $(141,208) $                     -  $(1,178,115)
Net loss  -   -   -   -   (166,099)  -   -   (166,099)
Foreign currency translation  -   -   -   -   -   6,597   -   6,597 
Balance at March 31, 2021  19,285,714   19,286   1,549,018   -   (2,771,310)  (134,611)  -   (1,337,617)
Net loss  -   -   -   -   (222,081)  -   -   (222,081)
Foreign currency translation  -   -   -   -   -   (19,893)  -   (19,893)
Balance at June 30, 2021  19,285,714   19,286   1,549,018   -   (2,993,391)  (154,504)  -   (1,579,591)
Net loss  -   -   -   -   (107,302)  -   -   (107,302)
Foreign currency translation  -   -   -   -   -   (3,676)  -   (3,676)
Balance at September 30, 2021  19,285,714  $19,286  $1,549,018  $-  $(3,100,693) $(158,180) $-  $(1,690,569)

 

The accompanying notes to the unaudited financial statements are an integral part of these consolidated financial statements.

 

3

 

 

CHINA HERB GROUP HOLDINGS CORPORATIONTENGJUN BIOTECHNOLOGY CORP. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

  For the Nine Months Ended 
  September 30, 
  2022  2021 
CASH FLOWS FROM OPERATING ACTIVITIES      
Net income (loss) $7,981,193  $(495,482)
Adjustments to reconcile net loss to net cash provided by operating activities:        
Depreciation  237,750   235,666 
Changes in net assets and liabilities:        
Inventories  1,492,095   (162,218)
Prepaid taxes  664,014   (16,805)
Loan to third parties  (23,056,740)  - 
Prepaid expenses and other assets  (24,192)  (24)
Advance to suppliers  (3,621)  (122,611)
Accounts payable  2,485,552   (198)
Taxes payable  14,336,944   33,600 
Advance from customers  32,551   - 
Accrued liabilities and other payable  (120,937)  208,362 
Net cash provided by (used in) operating activities  4,024,609   (319,710)
         
CASH FLOWS FROM INVESTING ACTIVITIES:        
Purchase of property and equipment  (9,570)  (42,611)
Payment for construction in progress  (241,119)  (237,094)
Net cash used in investing activities  (250,689)  (279,705)
         
CASH FLOWS FROM FINANCING ACTIVITIES        
Proceeds from sale of common stock  2,500,000   - 
Repayment of short-term bank loan  -   (463,671)
Proceeds from short-term loan from third parties  -   1,031,514 
Capital contribution  300,000   - 
(Repayment of) proceeds from loans from related parties  (2,674,670)  44,160 
Net cash provided by financing activities  125,330   612,003 
         
EFFECT OF EXCHANGE RATE CHANGE ON CASH AND CASH EQUIVALENTS  (288,850)  132 
         
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS  3,610,400   12,720 
         
CASH AND CASH EQUIVALENTS, BEGINNING BALANCE  285,568   6,238 
CASH AND CASH EQUIVALENTS, ENDING BALANCE $3,895,968  $18,958 
         
SUPPLEMENTAL DISCLOSURES:        
Income tax paid $-  $- 
Interest paid $-  $4,961 

The accompanying notes are an integral part of these consolidated financial statements.


TENGJUN BIOTECHNOLOGY CORP. AND SUBSIDIARIES

NOTES TO UNAUDITEDCONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2017(UNAUDITED)

(UNAUDITED)

NOTE 1. ORGANIZATION AND NATURE OF BUSINESS

 

NOTE 1 - Organization

Tengjun Biotechnology Corp. (formerly known as China Herb Group Holdings Corporation, (thethe “Company”) was incorporated under the name “Island Radio, Inc”Inc.” under the laws of the State of Nevada on June 28, 20102010. On December 9, 2019, the Company changed its corporate name to Tengjun Biotechnology Corp. (“Tengjun”).

 

Tengjunxiang Biotechnology Ltd. (“Tengjunxiang”) is a holding company incorporated in the Cayman Islands on July 19, 2021. On August 5, 2021, Tengjunxiang formed a wholly-owned subsidiary, Tengjunxiang Biotechnology HK Limited (“Tengjunxiang HK”), under the laws of Hong Kong. Shandong Minfu Biology Science and Technology Co., Ltd. (“Shandong Minfu”) is a company incorporated under the laws of the People’s Republic of China (the “PRC”) on August 29, 2021. Tengjunxiang HK owns all of the equity interests in Shandong Minfu, a wholly-foreign owned entity formed (“WFOE”) under the laws of PRC. 

Shandong Tengjunxiang Biotechnology Co., Ltd (“Shandong Tengjunxiang”) was incorporated under the laws of PRC on June 27, 2012, Eric R. Boyer2014. Jinxiang County Kanglong Water Purification Equipment Co., Ltd (“Jinxiang Kanglong”), a wholly-owned subsidiary of Shandong Tengjunxiang, was formed under the laws of the PRC on January 6, 2015. Shandong Tengjunxiang and Nina Edstrom (collectively,Jinxiang Kanglong have been under common control. Shandong Tengjunxiang and its subsidiary, Jinxiang Kanglong are primarily engaged in processing, packaging, distribution and sale of dandelion teas, and producing and sale of water purifiers in China, and plans to increase its tea processing and water purifier production lines, and expand its sales channels in the “Sellers”), who were thennext one to two years.

On December 15, 2021, all shareholders and the major shareholdersBoard of Shandong Tengjunxiang agreed to increase its registered capital to RMB 100 million, of which RMB 94.95 million shall be contributed by Shandong Minfu and the remaining RMB 5.05 million shall be contributed by fourteen other shareholders. On December 16, 2021, Tengjunxiang completed its restructuring transaction (the “Restructuring Transaction”). As a result of the Restructuring Transaction, Tengjunxiang, through its subsidiaries, directly owns 94.95% of the ownership of Shandong Tengjunxiang and therefore became the controlling shareholder of Shandong Tengjunxiang.

All of the entities of the Restructuring Transaction are under common control of Mr. Xianchang Ma, the controlling shareholder of Tengjunxiang, before and after the Restructuring Transaction, which results in the consolidation of Tengjunxiang and its subsidiaries and has been accounted for as a reorganization of entities under common control at carrying value and for accounting purpose, the reorganization was accounted for as a recapitalization. The consolidated financial statements are prepared on the basis as if the Restructuring Transaction became effective as of the beginning of the first period presented in the accompanying consolidated financial statements.

On December 23, 2021, the Company entered into a Share PurchasePurchase/Exchange Agreement (the “Share Exchange Agreement”) with Chin Yung Kong, Qiuping LuTenjunxiang, and Fumin Feng (collectively, the “Purchasers”eleven shareholders of Tengjunxiang (the “Selling Shareholders”), pursuant to which the Sellers sold. The Selling Shareholders collectively owned 100% of all issued and outstanding shares of Tengjunxiang (the “Tengjunxiang Shares”).  Pursuant to the Purchasers an aggregate 4,000,000Share Exchange Agreement, the Selling Shareholders jointly agreed to sell or transfer to the Company one hundred percent (100%) of the Tengjunxiang Shares in exchange for a total of 19,285,714 shares of the Company’s common stockstock. As a result of such exchange (the “Stock Exchange”), Tengjunxiang has become a wholly-owned subsidiary of the Company which representedand the Selling Shareholders collectively have received 19,285,714 shares of the Company’s common stock, representing approximately 93%29.53% of the then total issued and outstanding stockshares of the Company, for a total purchase price of $159,970 (the “Change in Control”). As result of this share purchase transaction, Chin Yung Kong, Qiuping Lu and Fumin Feng became the controlling shareholders of the Company.Company’s common stock.

 

The Company’s original business plan wasIn connection with the acquisition of Tengjunxiang pursuant to become a commercial FM radio broadcaster. Subsequently, following the Change in Control,Share Exchange Agreement, the Company changedwith its subsidiaries commenced its business planoperations in processing, packaging, distribution and intended to become a medicalsale of dandelion teas, producing and spa company with a focus on Asia. However, after consultation withsale of water purifiers in China through Tengjunxiang and its professional and business advisorssubsidiaries in the United States and the People’s Republic of China. The acquisition of Tengjunxiang is treated as a reverse acquisition (the “Reverse Acquisition”).

COVID-19

A novel strain of coronavirus, or COVID-19, was first identified in China in December 2019, and subsequently declared a pandemic on March 11, 2020 by the World Health Organization. As a result of the COVID-19 pandemic, all travels had been severely curtailed to protect the health of the Company’s management decided duringemployees and comply with local government guidelines. The COVID-19 pandemic has had an adverse effect on the third quarterCompany’s business. Although China has already begun to recover from the outbreak of 2014COVID-19 and the Company’s business has gone back to normal, the epidemic continues to spread on a global scale and there is a risk of the epidemic returning to China in the future, thereby causing further business interruption. The full impact of the pandemic on the Company’s business, operations and financial results depends on various factors that this would no longer be its plan of operations. The Company’s plan of operations iscontinue to evaluate various industries, geographic and market opportunities. This may take the form of acquiring a business, being acquired by an existing business or developing a business organically. Any such efforts may require significant capital,evolve, which the Company currently lacks. Theremay not be able to accurately predict for now.


NOTE 2. GOING CONCERN

These consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the Company’s accompanying consolidated financial statements, the Company has just started to generate revenues and turned around to be profitable since 2022. However, the Company still had working capital deficit of $441,156 as of September 30, 2022. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund its operating until it becomes sustainably profitable. The Company can give no assuranceassurances that any such opportunity will become available. Thereadditional capital that it is also no assurance that,able to obtain, if any, opportunity becomes available,will be sufficient to meet its needs.

If the Company is unable to successfully become sustainably profitable, or unable to raise additional capital or secure additional lending, the Company may need to curtail or cease its operations. The Company believes that these matters raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

In order to continue as a going concern, the Company will have the financial andneed, among other things, additional capital resources. Management plans to obtain such resources available to take advantage of such opportunity, since the Company’s has extremely limited liquidity. Through September 30, 2017,for the Company has no revenuesinclude obtaining capital from the sale of its equity, and short-term and long-term borrowings from banks, stockholders or operation.other related parties. However, management cannot provide any assurance that the Company will be successful in accomplishing any of its plans.

NOTE 2 - Summary of Significant Accounting Policies3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Unaudited Interim Financial InformationBasis of Accounting

 

The consolidated financial statements and accompanying balance sheetsnotes are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

Principles of consolidation

The consolidated financial statements include the financial statements of Tengjun Biotechnology Corp., Tengjunxiang and its 100% owned subsidiaries, Tengjunxiang HK and WOFE, and its 94.95% owned subsidiaries, Shandong Tengjunxiang and Jinxiang Kanglong. All inter-company transactions and balances are eliminated in consolidation.

Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the amount of revenues and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made. However, actual results could differ materially from those results.

Reclassification

Certain classifications have been made to the prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit.

Cash and Cash Equivalents

The Company considers all cash on hand and in banks, certificates of deposit with banks and other highly-liquid investments with maturities of three months or less, when purchased, to be cash and cash equivalents. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant risks on its cash in bank accounts.

Advance to suppliers

The Company makes advances to certain vendors for construction and purchase of equipment. The Company had advance to suppliers of $509,377 and $564,846 as of September 30, 2017, statements2022 and December 31, 2021, respectively. Based on management’s evaluation, no allowance for advances to suppliers was recorded as of operationsSeptember 30, 2022 and December 31, 2021.


Inventories

The Company’s inventories primarily consist of dandelion teas and water purifiers. Inventories are valued at the lower of cost (determined on a weighted average basis) and net realizable value. Inventories mainly consist of raw materials, goods in process, and finished goods. The Company reviews its inventories regularly for possible obsolete goods and establishes reserves when determined necessary. No reserve for inventory was established as of September 30, 2022 and December 31, 2021.

Property and Equipment

Property and equipment are recorded at cost less accumulated depreciation. Gains or losses on disposals are reflected as gain or loss in the period of disposal. All ordinary repair and maintenance costs are expensed as incurred.

Depreciation for financial reporting purposes is provided using the straight-line method over the estimated useful lives of the assets:

Estimated
Useful
Life
Buildings and improvements3-5 years
Machinery and equipment3-10 years
Office furniture and equipment3 years
Vehicles5 years

Costs incurred in constructing new facilities, including progress payments and other costs related to construction, are capitalized and transferred to property, plant and equipment on completion, at which time depreciation commences.

Construction in Progress

Construction in progress represents direct costs of construction, interest and design fees incurred. No interest was capitalized for the nine months ended September 30, 2022 and 2021. Capitalization of these costs ceases and the construction in progress is transferred to property, plant, and equipment when substantially all the activities necessary to prepare the assets for their intended use are completed. No depreciation is recognized until it is completed and ready for intended use. Construction in progress as of September 30, 2022 and December 31, 2021 was $8,044,587 and $8,726,299, respectively.

Impairment of Long-lived Assets

The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable through the estimated undiscounted cash flows expected to result from the use and eventual disposition of the assets. Whenever any such impairment exists, an impairment loss will be recognized for the amount by which the carrying value exceeds the fair value. There was no impairment for the nine months ended September 30, 2022 and 2021 based on management’s evaluation. 

Value added tax (“VAT”)

All China-based enterprises are subject to a VAT imposed by the PRC government on their domestic product sales and services. The Company’s subsidiaries in the PRC are subject to VAT at rates ranged from 0% to 17% on proceeds received from customers, and are entitled to a deduction for VAT already paid or borne on the products purchased by them. The VAT payable will be presented on the balance sheets when input VAT is less than the output VAT. Receivable balance, prepaid VAT, will be presented on the balance sheets when input VAT is larger than the output VAT.

Advances from customers

Payments received before all the relevant criteria for revenue recognition are satisfied are recorded as advance from customers. When all revenue recognition criteria are met, the advances from customers are recognized as revenue.


Revenue Recognition

The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers. To determine the revenue to be recognized, the Company applies the following five-step model:

identify arrangements with customers;

identify performance obligations;

determine transaction price;

allocate transaction price to the separate performance obligations in the arrangement, if more than one exists; and

recognize revenue as performance obligations are satisfied.

The Company generates revenues mainly from sales of packaged dandelion teas and water purifiers. During the three and nine months ended September 30, 20172022, the Company also engaged in the sale of certain nutraceutical products and 2016,water treatment accessories. Revenue from the sales of goods is recognized when the control over the promised goods is transferred to customers.

Cash payments received or due from customers before revenue recognized are recorded as advances from customers. The advance from customers is recognized as revenue when the Company’s performance obligation is completed.

Cost of goods sold

Cost of goods sold consists primarily of cost of goods purchased, direct raw material cost, direct labor cost, and cost of manufacturing overheads including the depreciation of production equipment.

Selling and marketing expenses

Selling and marketing expenses primarily consist of advertising costs, agency fees, costs for promotional materials, and commission costs made to sales force.

Advertising expenses are charged to the consolidated statements of cash flowsoperations and comprehensive loss in the period incurred. The amounts of advertising expenses incurred were $316 and $8,622 for the three months ended September 30, 2022 and 2021, respectively. The amounts of advertising expenses incurred were $4,470 and $25,268 for the nine months ended September 30, 20172022 and 2016,2021, respectively.

Commission expense primarily consists of commission costs made to independent sales force. The amount of commission expense incurred were $28,990,675 and $0 for the three months ended September 30, 2022 and 2021, respectively. The amount of commission expense incurred were $75,297,357 and $0 for the nine months ended September 30, 2022 and 2021, respectively.

General and administrative expenses

General and administrative expenses primarily consist of payroll and benefit costs for corporate employees, legal, consulting, professional expenses, rental expenses and other corporate overhead costs.

Concentration of Credit Risk

The operations of the Company are unaudited. These unaudited interim financial statements have been prepared in accordance with accounting principles acceptedprimarily in the United States of America (“U.S. GAAP”). In the opinion ofPRC. Accordingly, the Company’s management, the unaudited interimbusiness, financial statements have been prepared on the same basis as the audited financial statementscondition, and included all adjustments necessary for the fair presentation of the Company’s statement of financial position at September 30, 2017 and its results of operations may be influenced by the political, economic, and itslegal environments in the PRC, and by the general state of the PRC economy.

The Company has cash flows foron hand and demand deposits in accounts maintained with state-owned banks within the period ended September 30, 2017.PRC. Cash in state-owned banks is covered by insurance up to RMB 500,000 ($72,500) per bank. The results for the period ended September 30, 2017Company has not experienced any losses in such accounts and believes they are not necessarily indicative of the resultsexposed to be expected for the fiscal year ending December 31, 2017.any risks on their cash in these bank accounts.

 

Basis


The Company generated total revenue of Presentation

The accompanying financial statements have been prepared in accordance with U.S. GAAP for financial information$36,418,104 and in accordance with Regulation S-X promulgated by the Securities and Exchange Commission (the “SEC”). They reflect all adjustments which are, in the opinion of the Company’s management, necessary for a fair presentation of the financial position as of September 30, 2017 and operating results for$91,992,680 during the three and nine months ended September 30, 20172022, respectively. No customer accounted for over 10% of total revenue during the three and 2016.nine months ended September 30, 2022.

 

UseDuring the three months ended September 30, 2022, the Company had one major supplier that accounted for over 10% of Estimatesits total purchases.

 

Supplier Net purchase for the
three months ended
September 30,
2022
  % of total
purchase
 
A $1,657,070   88%

During the nine months ended September 30, 2022, the Company had two major suppliers that accounted for over 10% of its total purchases.

Supplier Net purchase for the
nine months ended
September 30,
2022
  % of total
purchase
 
A $2,662,345   85%
B  313,550   10%

No supplier accounted for over 10% of total purchase during the three and nine months ended September 30, 2021.

Income Taxes

The accompanyingCompany accounts for income taxes using an asset and liability approach which allows for the recognition and measurement of deferred tax assets based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial statementsreporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will either expire before the Company is able to realize their benefits, or that future deductibility is uncertain.

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer met. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred.

Related parties

The Company follows ASC 850, “Related Party Disclosures,” for the identification of related parties and disclosure of related party transactions. Parties are related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common control or significant influence, such as a family member or relative, shareholder, or a related corporation.

Foreign Currency Translation

The Company uses the United States dollar (“U.S. dollars”) for financial reporting purposes. The functional currency of the Company have been preparedand its subsidiaries is the Chinese Yuan or Renminbi (“RMB”). The Company’s subsidiaries maintain their books and records in accordance with generally accepted accounting principlestheir functional currency, being the primary currency of the economic environment in which their operations are conducted. For the Company and its subsidiaries whose functional currencies are other than the U.S. dollar, all asset and liability accounts were translated at the exchange rate on the balance sheet date; stockholders’ equity is translated at the historical rates and items in the United Statesincome statement and cash flow statements are translated at the average rate in each applicable period. Translation adjustments resulting from this process are included in accumulated other comprehensive income in the statement of America. Becauseshareholders’ equity. The resulting translation gains and losses that arise from exchange rate fluctuations on transactions denominated in a precise determinationcurrency other than the functional currency are included in the results of many assets and liabilities is dependent upon future events, the preparation of financial statements for a period necessarily involves the use of estimates which have been made using careful judgment. Actual results may vary from these estimates.operations as incurred.

 

4

 

 

Fair ValueValues of Financial Instruments

 

ASC 820 “Fair Value Measurements” anddefines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 825, Financial Instruments,820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. It establishes a fair value hierarchy based on the levelASC 820 describes three levels of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. It prioritizes the inputs into three levels that may be used to measure fair value:value:

 

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.liabilities.

 

Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets orand liabilities in active markets; quoted prices for identical assetsmarkets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs that are observable or can be derived principally from, or corroborated by, observable market data.

 

Level 3 applies– inputs that are unobservable

The Company’s financial instruments primarily consist of cash and cash equivalents, advances to assets or liabilities for which there are unobservable inputssuppliers, prepaid expenses, other receivable, accounts payable, accrued expenses, other payables, and related party borrowings. As of the balance sheet dates, the estimated fair values of the financial instruments were not materially different from their carrying values as presented on the balance sheets. This is attributed to the valuation methodologyshort maturities of the instruments and that are significantinterest rates on the borrowings approximate those that would have been available for loans of similar remaining maturity and risk profile at respective balance sheet dates.

Lease

The Company adopted FASB Accounting Standards Codification, Topic 842, Leases (“ASC 842”) using the modified retrospective approach, electing the practical expedient that allows the Company not to restate its comparative periods prior to the measurementadoption of the fairstandard on January 1, 2019.

The new leasing standard requires recognition of leases on the consolidated balance sheets as right-of-use (“ROU”) assets and lease liabilities. ROU assets represent the Company’s right to use underlying assets for the lease terms and lease liabilities represent the Company’s obligation to make lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value and future minimum lease payments over the lease term at commencement date. The Company’s future minimum based payments used to determine the Company’s lease liabilities mainly include minimum based rent payments. As most of the Company’s leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at commencement date in determining the present value of the assets or liabilities.lease payments.

 

AsThe adoption of September 30, 2017 and December 31, 2016,ASC 842 had no material impact on the Company believes thatCompany’s consolidated balance sheets, results of operations or cash flows. In addition, the recorded valuesadoption of allASC 842 did not result in a cumulative-effect adjustment to the opening balance of its financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.

DescriptionLevel 1Level 2Level 3Total
Realized
Loss
September 30, 2017----
December 31, 2016----
Total----

ASC 825-10 “Financial Instruments”, allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option)retained earnings (accumulated deficit). The fair value option may be electedOperating lease cost is recognized as a single lease cost on an instrument-by-instrumenta straight-line basis over the lease term and is irrevocable, unless a new election date occurs. If the fair value option is electedrecorded in selling, general and administrative expenses. Variable lease payments for an instrument, unrealized gainscommon area maintenance, property taxes and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.

Cash and Cash Equivalents

For purposes of the statement of cash flows, the Company considers highly liquid financial instruments purchased with a maturity of three months or less to be cash equivalents. As of September 30, 2017 and December 31, 2016, the Company had no cash equivalents.

Prepaid Expenses

Prepaidother operating expenses relate to cash paid in advance for annual listing fee. These amounts are recognized as expense over the related service periods. At September 30, 2017 and December 31, 2016, prepaid expenses amounted $5,833 and $4,367, respectively.

Advances for common stock purchases

Advances for common stock purchases consist of prepayments from investors for the purchase of common stock prior to the signing of a stock subscription agreement which was signed afterin the period end. The Company reclassified to equitywhen the advances for common stock purchases at the time the stock subscription was signed. At September 30, 2017changes in facts and December 31, 2016, the Company had advances for common stock purchases of $2,937 and $0, respectively.

Income Taxes

Deferred income tax assets and liabilities arise from temporary differences associated with differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current or non-current, depending upon the classification of the assets or liabilities to which they relate. Deferred tax assets and liabilities not related to an asset or liability are classified as current or non-current dependingcircumstances on the periods in which the temporary differencesvariable lease payments are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

The Company follows the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740-10 “Uncertainty in Income Taxes” (ASC 740-10). Certain recognition thresholds must be met before a tax position is recognized in the financial statements. An entity may only recognize or continue to recognize tax positions that meet a "more-likely-than-not" threshold. As of September 30, 2017 and December 31, 2016, the Company does not believe it has any uncertain tax positions that would require either recognition or disclosure in the accompanying financial statements.based occur.

 

5

Segment Reporting

ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s chief operating decision maker organizes segments within the Company for making operating decisions assessing performance and allocating resources. Reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company.

The Company manages its business as two operating segments, dandelion teas and water purifier, all of which are located in the PRC. All of its revenues are derived in the PRC. All long-lived assets are located in PRC.


 

Loss

The following table shows the Company’s operations by business segment for the three and nine months ended September 30, 2022 and 2021:

  For the  For the 
  Three Months Ended  Nine Months Ended 
  September 30,  September 30,  September 30,  September 30, 
  2022  2021  2022  2021 
Net revenue            
Dandelion teas $36,431,512  $-  $91,339,855  $- 
Water purifier  (13,408)  -   652,825   - 
Total revenues, net $36,418,104  $-  $91,992,680  $- 
                 
Cost of goods sold                
Dandelion teas $2,208,809  $-  $5,939,300  $- 
Water purifier  (1,505)  -   77,017   - 
Total cost of goods sold $2,207,304  $-  $6,016,317  $- 
                 
Gross profit (loss)                
Dandelion teas $34,222,703  $-  $85,400,555  $- 
Water purifier  (11,903)  -   575,808   - 
Gross profit $34,210,800  $-  $85,976,363  $- 
                 
Operating expenses                
Dandelion teas $29,188,532  $89,216  $75,447,666  $432,713 
Water purifier  10,996   18,334   440,478   55,520 
Total operating expenses $29,199,528  $107,550  $75,888,144  $488,233 
                 
Income (loss) from operations                
Dandelion teas $5,034,171  $(89,216) $9,952,889  $(432,713)
Water purifier  (22,899)  (18,334)  135,330   (55,520)
Income (loss) from operations $5,011,272  $(107,550) $10,088,219  $(488,233)

  As of
September 30,
  As of
December 31,
 
Segment assets 2022  2021 
Dandelion teas $34,680,003  $12,817,675 
Water purifier  788,219   958,530 
Total assets $35,468,222  $13,776,205 

Income (Loss) per Share Calculation

 

Basic net lossincome (loss) per common share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted earnings (loss) per shares is computed similar to basic lossearnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.

Recent Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326), which requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022. Early application will be permitted for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently evaluating the impact that the standard will have on its consolidated financial statements.

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848) (“ASU 2020-04”). ASU 2020-04 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. The Company continues to evaluate the impact of the guidance and may apply the elections as applicable as changes in the market occur.


NOTE 4. INVENTORIES, NET

Inventories consisted of the following: 

  September 30,  December 31, 
  2022  2021 
Raw materials $266,563  $300,918 
Work in process  400,840   300,711 
Finished goods  710,008   2,482,528 
   1,377,411   3,084,157 
Less: allowance for obsolete inventories  -   - 
Inventories, net $1,377,411  $3,084,157 

NOTE 5. PROPERTY, PLANT, AND EQUIPMENT, NET

Property, plant, and equipment consisted of the following: 

  September 30,  December 31, 
  2022  2021 
       
Buildings $14,129  $15,771 
Machinery and equipment  606,864   675,878 
Office equipment  132,481   144,072 
Vehicles  788,282   879,016 
   1,541,756   1,714,737 
Less: Accumulated depreciation  (1,151,714)  (1,039,181)
Property and equipment, net $390,042  $675,556 

Depreciation expense for the three months ended September 30, 2022 and 2021 were $73,809 and $80,318, respectively. Depreciation expense for the nine months ended September 30, 2022 and 2021 were $237,750 and $235,666, respectively.

NOTE 6. PREPAID TAXES

Prepaid taxes as of September 30, 2022 and December 31, 2021, primarily consisted of prepaid VAT in the amount of $0 and $688,272, respectively, which can be used to offset VAT payable when the Company incurs sales.

NOTE 7. LOAN TO THIRD PARTIES

During the nine months ended September 30, 2017 and 2016,2022, the Company hadmade loans to various individual sales agents in the aggregate amount of $21,409,853 pursuant to the agreements with each of the sales agents. The loans were made to each of the sales agents for the purpose of market expansion, and all loans shall be repaid in full before December 31, 2022. These loans are unsecured and bear no dilutive financial instruments issued or outstanding.interest.

NOTE 8. SHORT-TERM LOAN

 

Recent Accounting PronouncementsOn March 17, 2020, Shandong Tengjunxiang and China Construction Bank entered into a one-year bank loan agreement in an amount of RMB 3,000,000, equivalent to $459,770. The term started March 17, 2020 with the maturity date on March 17, 2021. The loan balance bore an interest rate of 4.025% per annum. The Company repaid the loan together with the accrued interest in full on March 17, 2021.

 

Accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

NOTE 3 - Going Concern

The Company has minimal operations, and as such has devoted most of its efforts since its inception to developing its business plan, issuing common stock, attempting to raise capital, establishing its accounting systems and other administrative functions.

As of September 30, 2017, the Company had $0 in cash and has been funding its working capital needs from loans from related parties. The Company is seeking sources of funding. Without limiting its available options, future equity financings will most likely be through the sale of additional shares of its common stock. It is possible that the Company could also offer warrants, options and/or rights in conjunction with any future issuances of its common stock. However, the Company can give no assurance that financing will be available to it, and if available, in amounts or on terms acceptable to the Company.

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The Company has not established a source of revenues sufficient to cover its operating costs, and as such, has incurred an operating loss since its inception. Further, as of September 30, 2017, the Company had a working capital deficit, accumulated deficit and stockholders’ deficit of $212,580, $409,481 and $212,580, respectively. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments or classifications that may result from the possible inability of the Company to continue as a going concern.

NOTE 4 - Related Party Transactions

Related Parties Loans

In year 2013, Chin Yung Kong, the director and shareholder of the Company, advanced $20,000 to the Company for working capital purposes. These working capital advances of $20,000 are payable on demand and, at September 30, 2017 and December 31, 2016, reflected as related party loans on the accompanying balance sheets.

Starting from year 2014, Qiuping Lu, President, CEO, director and shareholder of the Company, advanced funds to the Company for working capital purposes. These working capital advances are payable on demand. As of September 30, 2017 and December 31, 2016, these working capital advances amounted to $181,376 and $175,072, respectively, are reflected as related party loans on the accompanying balance sheets.

During the three months ended September 30, 20172022 and 2016, in connection with these related party loans,2021, the Company imputed interest of $3,977 and $3,634, respectively, and recorded interest expense and an increase in additional paid-in capital.

of $0. During the nine months ended September 30, 20172022 and 2016, in connection with these related party loans,2021, the Company imputed interest of $11,694 and $10,003, respectively, and recorded interest expense of $0 and an increase in additional paid-in capital.$4,987, respectively.


NOTE 9. ACCRUED LIABILITIES AND OTHER PAYABLES

 

NOTE 5 – Stockholders’ Equity (Deficit)Accrued liabilities and other payables consisted of the following on September 30, 2022 and December 31, 2021:

 

  September 30,  December 31, 
  2022  2021 
Accrued taxes $13,366,389  $59,719 
Advance from employees  1,982   45,787 
Payable for construction and improvements  92,856   150,102 
Payable for machinery and equipment  126,703   58,327 
Accrued payroll  4,289   10,220 
Accrued professional fees  14,000   42,000 
Other  50,099   140,689 
Total $13,656,318  $506,844 

Preferred Stock

NOTE 10. INCOME TAX

 

United States

The Company was incorporated in the United States of America and is subject to United States federal taxation. The U.S. Tax Cuts and Jobs Act (the “Act”) was enacted on December 22, 2017. Effective in 2018, the Tax Act reduces the U.S. statutory tax rate from 35% to 21%.

Cayman Islands

Under the current laws of the Cayman Islands, the Company is not subject to tax on income or capital gain. Additionally, upon payments of dividends to the shareholders, no Cayman Islands withholding tax will be imposed.

Hong Kong

Tengjunxiang HK is incorporated in Hong Kong and is subject to Hong Kong Profits Tax on the taxable income as reported in its statutory financial statements adjusted in accordance with relevant Hong Kong tax laws. The applicable tax rate is 16.5% on its taxable income generated from operations in Hong Kong. The Company did not make any provisions for Hong Kong profit tax as there were no assessable profits derived from or earned in Hong Kong since inception. Additionally, payments of dividends by the subsidiary incorporated in Hong Kong to the Company are not subject to any Hong Kong withholding tax.

PRC

Effective on January 1, 2008, the PRC Enterprise Income Tax Law, EIT Law, and Implementing Rules impose an unified enterprise income tax rate of 25% on all domestic-invested enterprises and foreign investment enterprises in PRC, unless they qualify under certain limited exceptions. As such, starting from January 1, 2008, the Company’s subsidiaries in PRC are subject to an enterprise income tax rate of 25%. The Company had recorded income tax provision of $1,861,830 and $0 for the nine months ended September 30, 2022 and 2021.

Provision for income tax expense (benefit) consists of the following:

  For the Nine months Ended
September 30,
 
  2022  2021 
Current      
USA $-  $      - 
China  1,861,830   - 
Deferred        
USA  -   - 
China  -   - 
Total provision for income tax expense $1,861,830  $- 


The following is a reconciliation of the statutory tax rate to the effective tax rate:

  For the Nine months Ended 
  September 30, 
  2022  2021 
U.S. federal statutory income tax (benefit)  21.0%  (21.0)%
Foreign tax rate differential  4.1%  (4.0)%
Permanent difference  0.0%  -%
Utilization of net operating losses (NOL) carryover  (6.7)%  -%
Change in valuation allowances  0.5%  25.0%
Effective income tax rate  18.9%  -%

The Company periodically evaluates the likelihood of the realization of deferred tax assets, and adjusts the carrying amount of the deferred tax assets by the valuation allowance to the extent that the future realization of the deferred tax assets is not judged to be more likely than not. The Company considers many factors when assessing the likelihood of future realization of its deferred tax assets, including its recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income or loss, the carryforward periods available to the Company for tax reporting purposes, and other relevant factors.

As of September 30, 2022 and December 31, 2021, based on the weight of available evidence, including cumulative losses in recent years and expectations of future taxable income, the Company determined that it was more likely than not that its deferred tax assets would not be realized and have a 100% valuation allowance associated with its deferred tax assets.

NOTE 11. RELATED PARTY TRANSACTIONS AND BALANCES

The related party of the company with whom transactions are reported in these financial statements are as follows:

Name of IndividualRelationship with the Company
Xianchang MaMajor shareholder, CEO, director of the Company
Liuhong LiuBeneficial owner of the Company’s common stock
Pan ShiBeneficial owner of the Company’s common stock
Jin TianBeneficial owner of the Company’s common stock
Qiuping LuShareholder, former director and CEO

Due from related party:

  September 30,  December 31, 
  2022  2021 
      
Pan Shi $1,105  $         - 

Due from related party represent advances to its related parties working capital purpose. The balances are unsecured, non-interest bearing, and payable on demand.

Due to related parties:

  September 30,  December 31, 
  2022  2021 
       
Xianchang Ma $11,333,657  $15,193,647 
Qiuping Lu  85,313   328,869 
Liuhong Liu  -   5,619 
Pan Shi  -   3,055 
Jin Tian  60   68 
  $11,419,030  $15,531,258 

Due to related parties represent advances from its related parties for the Company’s payment for construction, purchase of equipment, and daily operating expenses. The balances are unsecured, non-interest bearing, and payable on demand.


NOTE 12. LEASE

The Company leased a facility under an operating lease arrangement. The lease has initial lease term of 2 years. The lease agreement expired in August 2021.

The following provides details of the Company’s lease expenses:

  Three Months Ended
September 30,
 
  2022  2021 
Operating lease expenses $         -  $412 

  Nine Months Ended 
  September 30, 
  2022  2021 
Operating lease expenses $           -  $2,885 

Other information related to leases is presented below:

  Nine Months Ended
September 30,
 
  2022  2021 
Cash Paid For Amounts Included In Measurement of Liabilities:      
Operating cash flows from operating leases $        -  $2,885 
         
Weighted Average Remaining Lease Term:        
Operating leases  -   - 
         
Weighted Average Discount Rate:        
Operating leases  -%  4.75%

NOTE 13. EQUITY

Preferred Stock

The total number of preferred shares authorized that may be issued by the Company is 5,000,000 shares with a par value of $0.001 per share.

 

As of September 30, 20172022 and December 31, 2016,2021, the Company had no shares of its preferred stock issued and outstanding.

 

Common Stock

 

The total number of common shares authorized that may be issued by the Company iswas 70,000,000 shares with a par value of $0.001 per share.

As On March 30, 2022, the board of September 30, 2017 and December 31, 2016,directors of the Company had 38,136,540 and 37,493,120adopted a resolution to increase its authorized capital from 70,000,000 to 200,000,000 shares of its common stock issuedby amending and outstanding.

restating the Company’s articles of incorporation.

 

Common Stock SoldIssued for CashReverse Merger

 

On August 10, 2017,December 23, 2021, the Company issued 19,285,714 shares of Company’s common stock to eleven Selling Shareholders pursuant to the Share Exchange Agreement with Tenjunxiang (see Note 1).

On July 7, 2022, the Company sold 643,420an aggregate of 25,000,000 shares of its common stock at a purchase price of $0.03$0.10 per share to severalnine investors pursuant to athe signed stock purchase agreement. Theagreements.

NOTE 14. SUBSEQUENT EVENTS

In October 2022, the Company did not engagesold an aggregate of 6,000,000 shares of its common stock at a placement agent with respectprice of $0.05 per share, to two investors pursuant to the sale. Therestricted stock agreements. As of September 30, 2022, the Company received proceedspayments of $19,303.$300,000 for the subscribed stock. These common shares have been issued in October 2022.

 

NOTE 6 – Subsequent Events

The CompanyManagement has evaluated subsequent events from the balance sheet date through the date which the financial statements were issuedare available to be issued. All subsequent events requiring recognition as of September 30, 2022 have been incorporated into these financial statements and has determined there are no additionalsubsequent events required to be disclosed.
that require disclosure in accordance with FASB ASC Topic 855, “Subsequent Events.”

6

 

 

ITEM 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion of the results of operations and financial condition should be read in conjunction with our condensed consolidated financial statements and notes thereto included in Item 1 of this part. This report, including the information incorporated by reference, contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. The use of any of the words “believe,” “expect,” “anticipate,” “plan,” “estimate,” and similar expressions are intended to identify such statements. Forward-looking statements include statements concerning our possible or assumed future results. The actual results that we achieve may differ materially from those discussed in such forward-looking statements due to the risks and uncertainties described in the Risk Factors section of this report, in Management’s Discussion and Analysis of Financial Condition and Results of Operations, and in other sections of this report, as well as in our annual report on Form 10-K. We undertake no obligation to update any forward-looking statements.

Overview

Corporate History and Structure

We havewere incorporated on June 28, 2010 in the State of Nevada under the name “Island Radio, Inc.” and changed our name to “China Herb Group Holdings Corporation” effective July 17, 2012. On December 9, 2019, the Company changed its corporate name to “Tengjun Biotechnology Corp.”

On June 27, 2012, Eric R. Boyer and Nina Edstrom (collectively, the “Sellers”), who were then the major shareholders of the Company, entered into a Share Purchase Agreement with Chin Yung Kong, Qiuping Lu and Fumin Feng (collectively, the “Purchasers”), pursuant to which the Sellers sold to the Purchasers an aggregate 4,000,000 shares of the common stock of the Company, which represented approximately 93% of the then total issued and outstanding stock of the Company, for a total purchase price of $159,970 (the “Change in Control”). As result of this share purchase transaction, Chin Yung Kong, Qiuping Lu and Fumin Feng became the controlling shareholders of the Company.

Acquisitions/Business Combinations

On December 23, 2021, the Company entered into a Share Purchase/Exchange Agreement (the “Share Exchange Agreement”) with Tengjunxiang Biotechnology Ltd. (the “Target”), a Cayman Islands corporation, and the Target’s eleven shareholders (the “Selling Shareholders”): Min Xing Biotechnolgy Ltd, Pastoral Technology Co., Ltd., Shu Zhilin Trading Co., Ltd., Teng Rui Xiang Bio-Tech Ltd., Aihua Trading Co., Ltd, Rock Climbing Technology, Langtaosha Trading Co., Ltd., Min Cheng Biotechnology Ltd, Kangfan Technology Co., Ltd., Chaorong Technology Co., Ltd., and Shengrui Biotechnology Co., Ltd. In accordance with the Share Exchange Agreement, on December 23, 2021, the Selling Shareholders collectively sold and transferred 500,000,000 ordinary shares of the Target, constituting one hundred percent (100%) of the issued and outstanding share capital of the Target, to the Company in exchange for 19,285,714 shares of Company’s common stock, par value $0.001 per share (the “Tengjun Shares”), at an agreed price of $0.19 per share of the Company’s common stock (the “Common Stock”) for a total valuation of $3,675,000 of the Target.

In connection with the acquisition of the Target pursuant to the Share Exchange Agreement, the Company is entering into the Chinese tea and water purifier business through its newly acquired subsidiary the Target Company, which owns four corporate entities: (i) Tengjunxiang Biotechnology HK Limited (“Tengjun HK”), a company formed in Hong Kong and wholly owned by the Target, (ii) Shandong Minfu Biotechnology Co., Ltd. (“WFOE”), a wholly foreign owned entity formed under the laws of China and wholly owned by Tengjun HK, (iii) Shandong Tengjunxiang Biotechnology Co., Ltd. (“Shangdong Tengjunxiang”), a company formed under the laws of China and 94.95% owned by WFOE, and (iv) Jinxiang County Kanglong Water Purification Equipment Co. Ltd. (“Kanglong”), a company formed under the laws of China and wholly-owned subsidiary of Shandong Tengjunxiang. The parties to this Agreement closed the transaction contemplated therein on December 23, 2021.

The Target was incorporated on July 19, 2021 under the laws of the Cayman Islands. The authorized capital stock of the Target is 500,000,000 ordinary shares, all of which were issued and outstanding prior to the closing of the Acquisition. Shangdong Tengjunxiang, our operating company, was formed on June 27, 2014, under the laws of China. Promptly after the Closing, the Target shall update the shareholder registration of the Target to effect the Share Exchange Agreement. The Share Exchange Agreement was signed and agreed by and among all of the shareholders and/or beneficial owners of the Target, the Target and the Company.

As a result of the consummation of the Acquisition on December 23, 2021 as discussed above, the Target became a wholly-owned subsidiary of the Company and the business of the Target became the business of the Company.


The diagram below illustrates our corporate structure following the Acquisition:

 

We had limited operations and are not currently generating anygenerated limited revenues from our business operations.operations before the quarter ended September 30, 2022. Our independent registered public accounting firm has issued a going concern opinion for the year ended December 31, 2016.2021. This means that our auditors believe there is substantial doubt that we can continue as an on-going business for the next 12 months. We do not anticipate generating significant revenues until we acquire a business, are acquired by an existing business or develop a business organically. Accordingly, we mustmay have to raise additional cash from various sources, other than operations.including operations, controlling shareholders’ investments and debt and equity financing from third party investors.

 

We presently are exploring other such sources of funding, including raising funds through a public offering, a private placement of securities, debt or a combination of the foregoing. If we are unable to raise additional capital, we will either have to suspend operations until we do raise the cash or cease operations entirely.


 

The following discussion should be read in conjunction with our Financial Statements and the notes thereto and the other information included in this Annual Report as filed with the SEC on Form 10-K.

 

Overview

Our original business plan was to become a commercial FM radio broadcaster. Subsequently, following a change in control, we changed our business plan and intended to become a medical and spa company with a focus on Asia. However, after consultation with our professional and business advisors in the United States and the People’s Republic of China, management decided during the third quarter of 2014 that this would no longer be our plan of operations. Our plan of operations is to evaluate various industries, and geographic and market opportunities. This may take the form of acquiring a business, being acquired by an existing business or developing a business organically. Any such efforts may require significant capital, which we currently lack. There is no assurance that any such opportunity will become available. There is also no assurance that, if any opportunity becomes available, we will have the financial and other resources available to take advantage of such opportunity, since we have extremely limited liquidity. Through September 30, 2017, we had no revenues or operations.

Results of Operations

 

Results of Operations – Three and Nine Months Ended September 30, 2017 and 2016

Revenues. As of2022 Compared to Three Months Ended September 30, 2017, we had not generated any revenues.2021

 

Operating Expenses. Forthe three months ended September 30, 2017, total operating expenses amounted to $5,856 as compared to $11,450The following table sets forth information from our statements of comprehensive income for the three months ended September 30, 2016, a decrease of $5,594 or 48.9%. For2022 and 2021:

  Three Months Ended    
  September 30,  Change 
  2022  2021  (Amount)  (Percent) 
Sales revenue $36,418,104  $-  $36,418,104   *%
Cost of Goods Sold  (2,207,304)  -   (2,207,304)  *%
Gross Profit  34,210,800   -   34,210,800   *%
Operating Expenses  (29,329,707)  (107,550)  (29,222,157)  27,171%
Operating Income (Loss)  4,881,093   (107,550)  4,988,643   (4,638)%
Interest Income (Expense)  6,273   18   6,255   34,750%
Other Income (Expense)  (7,144)  230   (7,374)  (3,206)%
Income Tax Provision  (1,265,644)  -   (1,265,644)   *%
Net Income (Loss)  3,614,578   (107,302)  3,721,880   (3,469)%
Comprehensive Income (loss) $3,168,527  $(110,978) $3,279,505   (2,955)%

Revenues 

We generated $36,418,104 and $0 in revenues for the ninethree months ended September 30, 2017,2022 and 2021, respectively. The Company did not generate any revenue during the three months ended September 30, 2021 due to the impact of COVID-19.

During the three months ended September 30, 2022, sales of dandelion teas, certain nutraceutical products, and water treatment accessories generated $36,431,512 in revenue, constituting approximately 100% of the total operatingrevenue for that quarter, and sales of water purifiers generated negative revenue of $13,408 due to sales returns, representing approximately 0% of the total revenue for such quarter.

The following is the sales breakdown by segment during the three months ended September 30, 2022 and 2021:

  For the three months ended 
  September 30, 
  2022  2021 
Dandelion teas  $36,431,512   100% $     -            -%
Water purifier  (13,408)  (0)%  -   -%
Total $36,418,104   100% $-     -%

Cost of Goods Sold 

Our cost of goods sold was $2,207,304 and $0 for the three months ended September 30, 2022 and 2021, respectively. During the three months ended September 30, 2022, cost of sales of dandelion teas, certain nutraceutical products, and water treatment accessories was $2,208,809, constituting approximately 100% of the total cost of goods sold, and cost of sales of water purifiers was $(1,505), representing approximately negative 0% of the total cost of goods sold due to the cost adjustment in connection with the sales returns. The Company did not incur any cost in the three months ended September 30, 2021 because there were no sales during the third quarter of 2021.


The following is the cost of goods sold breakdown by segment during the three months ended September 30, 2022 and 2021:

  For the three months ended 
  September 30, 
  2022  2021 
Dandelion teas $2,208,809   100% $-   -%
Water purifier  (1,505)  0%  -   -%
Total $2,207,304   100% $-   -%

Gross Profit

Our gross profit was $34,210,800 and $0 for the three months ended September 30, 2022 and 2021, respectively. The gross profit as a percentage of net revenue for the Dandelion teas was 94% for the three months ended September 30, 2022. The gross profit as a percentage of net revenue for the Water purifiers was approximately 89% for the three months ended September 30, 2022. 

The following table presents gross profit by segment for three months ended September 30, 2022 and 2021: 

  For the three months ended 
  September 30, 
  2022  2021 
Dandelion teas $34,222,703   100% $-   -%
Water purifier  (11,903)  (0)%  -   -%
Total $34,210,800   100% $-   -%

Selling and Marketing Expenses

Our selling and marketing expenses amounted to $29,817primarily consist of sales commission, advertising and product promotional expenses.

Our selling and marketing expenses were $28,990,991 for the three months ended September 30, 2022 as compared to $26,666$9,188 for the three months ended September 30, 2021. Our total selling and marketing expenses increased by $28,981,803 or 315,431% during the three months ended September 30, 2022, compared to the same period in 2021. Such increase in selling and marketing expenses was mainly due to the significant increase in sales commission.

General and administrative expenses

Our general and administrative expenses primarily consist of payroll and benefit costs for corporate employees, legal, consulting, professional expenses, rental expenses and other corporate overhead costs.

The general and administrative expenses was $338,716 for the three months ended September 30, 2022 as compared to $98,362 for the three months ended September 30, 2021. Our general and administrative expenses increased by $240,354 or 244% during the three months ended September 30, 2022, compared to the same period in 2021. Such increase in general and administrative expenses was mainly due to the increase in legal, accounting, printing, and stock transfer agent fees that were associated with the Company’s merger and SEC public disclosures.

Interest income (expense)

Interest income (expense) was $6,273 for the three months ended September 30, 2022 as compared to $18 for the three months ended September 30, 2021. Our total interest income increased by $6,255 or 34,750% during the three months ended September 30, 2022, compared to the same period in 2021. The increase in interest income was primarily due to the interest earned from the Company’s bank savings accounts.

Net Income (Loss) 

Our net income was $3,614,578 for the three months ended September 30, 2022 as compared to net loss of $107,302 for the three months ended September 30, 2021, increased by $3,721,880 or 3,469% as a result of the above factors.


Foreign Currency Translation Loss

We had $(446,051) in foreign currency translation loss during the three months ended September 30, 2022 as compared to $(3,676) in foreign currency translation loss during the three months ended September 30, 2021, reflecting a change of $442,375 or 12,034%. Such increase in foreign currency translation gain was primarily caused by the currency exchange rate fluctuation.

Results of Operations – Nine Months Ended September 30, 2022 Compared to Nine months Ended September 30, 2021

The following table sets forth information from our statements of comprehensive income for the nine months ended September 30, 2016, an increase of $3,151 or 11.8%. Since inception, our operating expenses primarily consisted of fees2022 and expenses related to complying with our ongoing SEC reporting requirements, which have consisted of accounting fees, transfer agent fees, filing fees,2021:

  Nine Months Ended    
  September 30,  Change 
  2022  2021  (Amount)  (Percent) 
Sales revenue $91,992,680  $-  $91,992,680   *%
Cost of Goods Sold  (6,016,317)  -   (6,016,317)  *%
Gross Profit  85,976,363   -   85,976,363   *%
Operating Expenses  (76,139,816)  (488,233)  (75,651,583)  15,495%
Operating Income (Loss)  9,836,547   (488,233)  10,324,780   (2,115)%
Interest Income (Expense)  13,694   (4,959)  18,653   (376)%
Other Income (Expense)  (7,218)  (2,290)  (4,928)  215%
Income Tax Provision  (1,861,830)  -   (1,861,830)   *%
Net Income (Loss)  7,981,193   (495,482)  8,476,675   (1,711)%
Comprehensive Income (loss) $7,479,203  $(512,454) $7,991,657   (1,559)%

Revenue

We generated $91,992,680 and consulting fees, etc.

Other expenses.During$0 in revenues for the threenine months ended September 30, 20172022 and 2016, we recorded $3,977 and $3,634, respectively, in imputed interest expenses related2021, respectively. The Company did not generate any revenue during the nine months ended September 30, 2021 due to advances outstanding to related parties. the impact of COVID-19.

During the nine months ended September 30, 20172022, sales of dandelion teas, certain nutraceutical products, and 2016, we recorded $11,694water treatment accessories generated $91,339,855 in revenue, constituting approximately 99% of the total revenue for that period, and $10,003, respectively,sales of water purifiers generated $652,825 in imputed interest expenses related to advances outstanding to related parties. These imputed interests were recorded in our financial statements under additional paid-in capital. revenue, representing approximately 1% of the total revenue for such period. 

 

Net Loss.DuringThe following is the threesales breakdown by segment during the nine months ended September 30, 20172022 and 2016, we had a net loss2021:

  For the nine months ended 
  September 30, 
  2022  2021 
Dandelion teas $91,339,855   99% $-         -%
Water purifier  652,825   1%  -   -%
Total $91,992,680   100% $-   -%

Cost of $9,833Goods Sold 

Our cost of goods sold was $6,016,317 and $15,084,$0 for the nine months ended September 30, 2022 and 2021, respectively. During the nine months ended September 30, 20172022, cost of sales of dandelion teas, certain nutraceutical products, and 2016, we had a net losswater treatment accessories was $5,939,300, constituting approximately 99% of $41,511the total cost of goods sold, and $36,669, respectively.

Liquidity and Capital Resources

Ascost of September 30, 2017, wesales of water purifiers was $77,017, representing approximately 1% of the total cost of goods sold. The Company did not haveincur any cash, while, we had liabilities of $218,413, and had a working capital deficit of $212,580. We expect to incur continued losses during the remainder of 2017, possibly even longer.

For cost in the nine months ended September 30, 2017 and 2016, net cash used in operating activities amounted to $28,544 and $37,638, respectively. We expect to require working capital2021 because there were no sales during the same period of approximately $50,000 over2021.


The following is the next 12 months to meet our financial obligations.

For the ninemonths ended September 30, 2017 and 2016, net cash providedcost of goods sold breakdown by financing activities amounted to $28,544 and $35,843, respectively. Forsegment during the nine months ended September 30, 2017, we received advance for future common stock subscriptions of $2,937, received proceeds from sale of common stock of $19,303,2022 and received proceeds from loans from officer of $28,544, and made repayments for loans from officer of $22,240. For the nine months ended September 30, 2016, we received cash from bank drafts of $36, proceeds from sale of common stock of $1,050 and proceeds from loans from officer of $34,757 for working capital purposes.

2021:

7

 

  For the nine months ended 
  September 30, 
  2022  2021 
Dandelion teas $5,939,300   99% $-   -%
Water purifier  77,017   1%  -   -%
Total $6,016,317   100% $-   -%

We have not generated any revenues from operations to date. It is not likely that we will generate any revenue until at least a business combination has been consummated. Even following a business combination, there is no guarantee that any revenues will be generated or that any revenues will be sufficient to meet our expenses. We may consider a business combination with a target company which itself has recently commenced operations, is a developing company in need of additional funds for expansion into new products or markets, is seeking to develop one or more new products or services, or is an established business which may be experiencing financial or operating difficulties

Gross Profit

Our gross profit was $85,976,363 and is in need of additional capital. 

The foregoing considerations raise substantial doubt about our ability to continue as a going concern.  We are currently planning on devoting the vast majority of our efforts to identifying, investigating and conducting due diligence on target companies; and negotiating, structuring, documenting and consummating a business combination. Our long-term ability to continue as a going concern is dependent upon our ability to develop additional sources of capital, complete a business combination and, thereafter, achieve profitable operations.

We believe that we will be able to meet these costs through cash on hand and additional amounts, as may be necessary, to be loaned by or invested in us by our stockholders, management and/or others. Currently, however, our ability to continue as a going concern is dependent upon our ability to generate future profitable operations and/or to obtain the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they come due.  Our ability to continue as a going concern is also dependent on our ability to find a suitable target company and enter into a business combination.  Management’s plan includes obtaining additional funds through a combination of sales of our equity securities before, contemporaneously with, or following, the consummation of a business combination; and borrowings, although we do not believe that we will be eligible to borrow funds from a bank until at least a business combination is consummated.  However, there is no assurance that any additional funding will be available on terms that are favorable to us or at all.

We currently rely on loans from our sole director and officer, Qiuping Lu. There is no guarantee that Ms. Lu will continue to lend us funds to meet our expenses in the future. Currently, we do not have any other arrangements for financing.  We have no assurance that future financing will be available to us on acceptable terms, or at all. If financing is not available to us on satisfactory terms or at all, we may be unable to develop operations or meet our expenses.  Additionally, any equity financing in which we might engage would result in dilution to our existing shareholders.

During the nine months ended September 30, 2017 and 2016, Ms. Lu, the sole director and officer of us, advanced an aggregate $28,544 and $34,757, respectively, to us to pay some of our expenses and for working capital purposes, and we repaid $22,240 and $0 respectively, to Ms. Lu. These advances in the aggregate amounts of $181,376 and $175,072, respectively, at September 30, 2017 and December 31, 2016, are payable on demand and are reflected as related party loans on the accompanying balance sheets.

Imputed interest of $3,977 and $3,634 was recorded for the three months ended September 30, 2017 and 2016, respectively, and the imputed interest was recorded as interest expense and an increase in additional paid-in capital, respectively. Imputed interest of $11,694 and $10,003 was recorded for the nine months ended September 30, 20172022 and 2016, respectively,2021, respectively. The gross profit as a percentage of net revenue for the Dandelion teas was 93% for the nine months ended September 30, 2022. The gross profit as a percentage of net revenue for the Water purifiers was approximately 88% for the nine months ended September 30, 2022. 

The following table presents gross profit by segment for nine months ended September 30, 2022 and 2021:

  For the nine months ended 
  September 30, 
  2022  2021 
Dandelion teas $85,400,555   99% $-   -%
Water purifier  575,808   1%  -   -%
Total $85,976,363   100% $-   -%

Selling and Marketing Expenses

Our selling and marketing expenses primarily consist of sales commission, advertising and product promotional expenses.

Our selling and marketing expenses were $75,301,827 for the nine months ended September 30, 2022 as compared to $26,066 for the nine months ended September 30, 2021. Our total selling and marketing expenses increased by $75,275,761 or 288,789% during the nine months ended September 30, 2022, compared to the same period in 2021. Such increase in selling and marketing expenses was mainly due to the significant increase in sales commission.

General and administrative expenses

Our general and administrative expenses primarily consist of payroll and benefit costs for corporate employees, legal, consulting, professional expenses, rental expenses and other corporate overhead costs.

The general and administrative expenses were $837,989 for the nine months ended September 30, 2022 as compared to $462,167 for the nine months ended September 30, 2021. Our general and administrative expenses increased by $375,822 or 81% during the nine months ended September 30, 2022, compared to the same period in 2021. Such increase in general and administrative expenses was mainly due to the increase in legal, accounting, printing, and stock transfer agent fees that were associated with the Company’s merger and SEC public disclosures.

Interest income (expense)

Interest income (expense) was $13,694 for the nine months ended September 30, 2022 as compared to $(4,959) for the nine months ended September 30, 2021, representing an increase from interest expense to interest income by $18,653, or 376% during the nine months ended September 30, 2022, compared to the same period in 2021, primarily due to the repayment of a short-term bank loan on March 17, 2021 and the imputed interest earned from Company’s bank savings accounts.


Net Income (Loss) 

Our net income was recorded$7,981,193 for the nine months ended September 30, 2022 as interest expensecompared to net loss of $495,482 for the nine months ended September 30, 2021, increased by $8,476,675 or 1,711% as a result of the above factors.

Foreign Currency Translation Loss

We had $(501,990) in foreign currency translation loss during the nine months ended September 30, 2022 as compared to $(16,972) in foreign currency translation loss during the nine months ended September 30, 2021, reflecting a change of $485,018 or 2,858%. Such increase in foreign currency translation gain was primarily caused by the currency exchange rate fluctuation.

Liquidity and Capital Resources

Working Capital

  September 30,  December 31,  Change 
  2022  2021  (Amount)  (Percent) 
             
Current Assets $27,222,418  $4,628,531   22,593,887   488%
Current Liabilities $27,663,574  $16,316,116   11,347,458   70%
Working Capital (deficit) $(441,156) $(11,687,585)  11,246,429   (96)%

Our working capital deficit was $441,156 as of September 30, 2022 as compared to $11,687,585 as of December 31, 2021, a decrease of $11,246,429 or 96%. The decrease in working capital deficiency is primarily due to the increase in cash inflow from revenue and the increase in the loans to third parties that are related to our operating activities during the nine months ended September 30, 2022.

Cash Flow from Operating Activities

Our net cash provided by operating activities were $4,024,609 for the nine months ended September 30, 2022 as compared to $319,710 of net cash used in operating activities for the nine months ended September 30, 2021, reflecting an increase of $4,344,319 or 1,359%. The increase was primarily due to the increase in additional paid-in capital, respectively.net income, the decrease in inventories, prepaid taxes, and increase in accounts payable and taxes payable, partially offset by the increase in loan to third parties during the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021.

  

Going Concern ConsiderationCash Flow from Investing Activities

 

Our independent registered public accounting firm has issued a going concern opinionnet cash used in their audit report dated March 27, 2017, which can be found in our Annual Report on Form 10-K filed with the SEC on March 27, 2017. This means that our auditors believe there is substantial doubt that we can continue as an on-going businessinvesting activities was $250,689 for the next 12 months. Our financial statements found within this Quarterly Report on Form 10-Q andnine months ended September 30, 2022 as compared to that of $279,705 for the aforementioned Annual Report on Form 10-K contain additional note disclosures describingnine months ended September 30, 2021, reflecting a decrease of $29,016 or 10%. The decrease in net cash used in investing activities was primarily due to the circumstances that leaddecrease in payment for acquisition of equipment during the nine months ended September 30, 2022 as compared to this disclosure by our independent auditors.those items in the nine months ended September 30, 2021. 

 

Contractual Obligations


Cash Flow from Financing Activities

Our net cash provided by financing activities were $125,330 for the nine months ended September 30, 2022 as compared to $612,003 of net cash provided by financing activities for the nine months ended September 30, 2021, representing a decrease of $486,673 or 80%. The decrease was primarily due to the repayment of loans from related parties during the nine months ended September 30, 2022.

Off-Balance Sheet Arrangements

As of September 30, 2017,2022, we had no contractual obligations.

Off –Balance Sheet Operations

As of September 30, 2017, we had nodid not have any off-balance sheet activitiesarrangements that have or operations.are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that is material to investors.

 

Critical Accounting Policies

The accompanying financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles (US GAAP) for financial information and in accordance with the Securities and Exchange Commission’s (SEC) Regulation S-X. We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of the unaudited financial statements.

Estimates

8

 

Use of Estimates

The preparation ofWe prepare our financial statements in conformity with accounting principles generally accepted inGenerally Accepted Accounting Principles (“GAAP”) of the United States, of Americawhich requires management to make certain estimates and assumptionsapply judgments. We base our estimates and judgments on historical experience, current trends and other factors that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilitiesmanagement believes to be important at the date oftime the financial statements are prepared. On a regular basis, we review our accounting policies and how they are applied and disclosed in our financial statements.

While we believe that the reported revenueshistorical experience, current trends and expenses duringother factors considered support the reporting periods. Becausepreparation of the use of estimates inherentour financial statements in the financial reporting process,conformity with GAAP, actual results maycould differ significantly from thoseour estimates. and such differences could be material.

 

CashInventories

Our inventories primarily consist of dandelion teas and Cash Equivalents

For purposeswater purifiers. Inventories are valued at the lower of the statementcost (determined on a weighted average basis) and net realizable value. Inventories consist of cash flows, we consider highly liquid financial instruments purchased with a maturity of three months or less to be cash equivalents.raw materials, goods in process, and finished goods. We review our inventories regularly for possible obsolete goods and establishes reserves when determined necessary. As of September 30, 20172022 and December 31, 2016, we had no cash equivalents.2021, the allowance for obsolete inventories was $0 and $0, respectively.

 

Fair ValueConstruction in Progress

Construction in progress represents direct costs of Financial Instruments

ASC 820, “Fair Value Measurements”construction, interest and ASC 825, Financial Instruments, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. It establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. It prioritizes the inputs into three levels that may be used to measure fair value:

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observabledesign fees incurred. No interest was capitalized for the asset or liability such as quoted prices for similar assets or liabilitiesthree and nine months ended September 30, 2022 and 2021. Capitalization of these costs ceases and the construction in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 3 appliesprogress is transferred to assets or liabilities for which there are unobservable inputsproperty, plant, and equipment when substantially all the activities necessary to the valuation methodology that are significant to the measurement of the fair value ofprepare the assets or liabilities.

Asfor their intended use are completed. No depreciation is recognized until it is completed and ready for intended use. Construction in progress as of September 30, 20172022 and December 31, 2016, we believe that2021 was $8,044,587 and $8,726,299, respectively.


Revenue Recognition

The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers. To determine the recorded values of all of our financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.revenue to be recognized, the Company applies the following five-step model:

 

Net Loss per Share Calculation

identify arrangements with customers;
identify performance obligations;
determine transaction price;
allocate transaction price to the separate performance obligations in the arrangement, if more than one exists; and
recognize revenue as performance obligations are satisfied.

 

Basic net loss per common shareThe Company generates revenues mainly from sales of packaged dandelion teas and water purifiers. During the three and nine months ended September 30, 2022, the Company also engaged in the sale of certain nutraceutical products and water treatment accessories. Revenue from the sales of goods is computed by dividingrecognized when the net loss attributablecontrol over the promised goods is transferred to customers.

Cash payments received or due from customers before revenue recognized are recorded as advances from customers. The advance from customers is recognized as revenue when the Company’s performance obligation is completed.

Related parties

The Company follows ASC 850, “Related Party Disclosures,” for the identification of related parties and disclosure of related party transactions. Parties are related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common stockholders by the weighted-average number of common shares outstandingcontrol or significant influence, such as a family member or relative, shareholder, or a related corporation.

Recent Accounting Pronouncements

See Note 3 to our unaudited consolidated financial statements for the period. Diluted earnings per shares is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issuedthree and if the additional common shares were dilutive. During the periods presented, we had no dilutive financial instruments issued or outstanding.nine months ending September 30, 2022 and 2021. 

 

Income Taxes


 

We account for income taxes pursuant to FASB ASC 740, “Income Taxes”. Under FASB ASC 740-10-25, deferred tax assets and liabilities are determined based on temporary differences between the bases of certain assets and liabilities for income tax and financial reporting purposes. The deferred tax assets and liabilities are classified according to the financial statement classification of the assets and liabilities generating the differences.

 

We maintain a valuation allowance with respect to deferred tax assets. We establish a valuation allowance based upon the potential likelihood of realizing the deferred tax asset and taking into consideration our financial position and results of operations for the current period. Future realization of the deferred tax benefit depends on the existence of sufficient taxable income within the carry-forward period under the Federal tax laws.

Changes in circumstances, such as us generating taxable income, could cause a change in judgment about its ability to realize the related deferred tax asset. Any change in the valuation allowance will be included in income in the year of the change in estimate.

Recently Issued Accounting Pronouncement

Accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. We do not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to our financial condition, results of operations, cash flows or disclosures.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable.

 

9

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures.

 

As of the end of the period covered by this report, we conducted an evaluation under the supervision and with the participation of our chief (principal) executive officer and principalchief (principal) accounting officer of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Exchange Act).

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be presented or detected on a timely basis.basis.

 

Based on management’s assessment, we have concluded that, as of September 30, 2017,2022, our disclosure controls and procedures were not effective in timely alerting management to the material information relating to us required to be included in our annual and interim filings with the SEC.SEC.

 

Our chief executive officer and principal financial officer have concluded that our disclosure controls and procedures had the following material weaknesses:weaknesses:

 

·Wewere unable to maintain any segregation of duties within our financial operations due to our reliance on limited personnel in the finance function. While this control deficiency did not result in any audit adjustments to our 20162021 interim or annual financial statements, it could have resulted in a material misstatement that might have been prevented or detected by a segregation of duties;

 

·Welack sufficient resources to perform the internal audit function and does not have an Audit Committee;Committee;

 

·We do not have an independent Board of Directors, nor do we have a board member designated as an independent financial expert. The Board of Directors is comprised of one (1) member who is also our only executive officer.  As a result, there is a lack of independent oversight of the management team, lack of independent review of our operating and financial results, and lack of independent review of disclosures made by us;

·Documentationof all proper accounting procedures is not yet complete; and

 

·We have no formal control process related to the identification and approval of related party transactions.

 

These weaknesses were identified in our Annual Report on Form 10-K for the year ended December 31, 2016.2021. These weaknesses have existed since our inception on June 28, 2010 and, as of September 30, 2017,2022, have not been remedied.remediated.

 

To the extent reasonably possible given our limited financial and personnel resources, we intend to take measures to cure the aforementioned material weaknesses, including, but not limited to, the following:following:

 

Consider the engagement of consultants to assist in ensuring that accounting policies and procedures are consistent across the organization and that we have adequate control over financial statement disclosures;disclosures;

 

Hireadditional qualified financial personnel, including a Chief Financial Officer, on a full-time basis;

 

Expandour board of directors to include additional independent individuals willing to perform directorial functions;functions; and

 

Increaseour workforce in preparation for commencing revenue producing operations.operations.

 

Since the recited remedial actions will require that we hire or engage additional personnel, these material weaknesses may not be overcome in the near-term due to our limited financial resources. Until such remedial actions can be realized, we will continue to rely on the limited advice of outside professionals and consultants.consultants.

 

Changes in Controls and Procedures

 

Therehave been no changes in our internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.reporting.

10

 

 

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

 

We are not currently a party to any lawsuit or proceeding which, in the opinion of management, is likely to have a material adverse effect on us or our business.

ITEM 1A. RISK FACTORS

 

Not applicable for smaller reporting companies.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

On August 10, 2017, weOctober 4, 2022, the Company entered into two restricted stock agreements (the “Restricted Stock Agreements”) pursuant to which the Company issued and sold 643,420a total of 6,000,000 shares of common stockthe Company’s Common Stock to a consultant and an independent contractor of the Company, at a purchase price of $0.03$0.05 per share for a total price of $300,000.

The foregoing description of the Restricted Stock Agreements does not purport to several investors pursuant to a stock purchase agreement. We did not engage a placement agent with respectbe complete and is qualified in its entirety by reference to the sale. We received proceedsentire Restricted Stock Agreement, a form of $19,303.which is filed as Exhibit 10.1 hereto, and incorporated herein by reference.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

ITEM 5. OTHER INFORMATION

 

None.

ITEM 6. EXHIBITS

 

Exhibit
Number
Description
10.1Form of Restricted Stock Agreement
 (a)Exhibits

31.1*Certification by theof Chief Executive Officer and Chief Financial Officer pursuant to Section 302Rule 13a-14(a) of the Sarbanes-Oxley Act of 2002 and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934
  
31.2*Certification by the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934
 
32.1**Certification of Periodic Financial Report by the Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.2002
  
101.INS101.INS*INLINE XBRL Instance DocumentINSTANCE DOCUMENT
  
101.SCH101.SCH*INLINE XBRL Taxonomy Extension Schema DocumentTAXONOMY EXTENSION SCHEMA DOCUMENT
  
101.CAL101.CAL*INLINE XBRL Taxonomy Extension Calculation Linkbase DocumentTAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
  
101.DEF101.DEF*INLINE XBRL Taxonomy Extension Definition Linkbase DocumentTAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
  
101.LAB101.LAB*INLINE XBRL Taxonomy Extension Label Linkbase DocumentTAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
  
101.PRE101.PRE*INLINE XBRL Taxonomy Extension Presentation Linkbase DocumentTAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

* filed herewith

 11 
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

*Filed along with this document
**The certification attached as Exhibit 32.1 accompanying this quarterly report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, shall not be deemed “filed” by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.


 

 

SIGNATURES

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereuntohereunto duly authorized.

 

 China Herb Group Holdings Corporation
(Registrant)Tengjun Biotechnology Corp.
  
Date: October 27, 2017November 14, 2022By:/s/ QIUPING LUXianchang Ma
Name:Xianchang Ma
Title:

Chief Executive Officer and

Chief Financial Officer

  

Qiuping Lu

President, Chief(Principal Executive Officer,

Principal Financial and
Chief Financial Officer Accounting Officer)

 

 

1227

 

iso4217:USD xbrli:shares